Pylotrip30 mg+1000 mg+500 mg

Established Indication

Pylotrip is a fixed-combination regimen (a proton pump inhibitor plus two antibiotics) indicated for the treatment of patients with Helicobacter pylori (H. pylori) infection and duodenal ulcer disease (active or a history within the past 5 years), to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence.

Not Indicated For

• Pylotrip is not indicated for isolated gastro-oesophageal reflux disease, dyspepsia, or peptic ulcer disease without confirmed H. pylori infection; a full triple-antibiotic course should not be used unless H. pylori infection has actually been demonstrated (by biopsy, stool antigen, or urea breath test).
• Pylotrip is not a standard first-line regimen in regions/patients with known high clarithromycin resistance; local resistance patterns should guide the choice of eradication regimen.

Pylotrip must always be used as directed by a physician for a confirmed indication; it should not be substituted for other acid-suppressive therapy alone.

Lansoprazole + Amoxicillin + Clarithromycin is supplied as a combination pack (or co-blistered kit) containing three separate medicines to be taken together for each dose:

• Lansoprazole delayed-release capsules 30 mg
• Amoxicillin capsules 500 mg (two capsules per dose, total 1 g)
• Clarithromycin tablets 500 mg

All three components of Lansoprazole + Amoxicillin + Clarithromycin are taken together, twice daily, for the duration of the eradication course.

Pylotrip is a triple-therapy combination used specifically for the eradication of Helicobacter pylori, a bacterium strongly associated with duodenal ulcer disease and, less commonly, gastric ulcer disease. It combines a proton pump inhibitor (lansoprazole), which reduces gastric acid secretion and raises intragastric pH, with two antibiotics (amoxicillin and clarithromycin) that act against H. pylori. Combining an acid suppressant with two antibiotics improves eradication rates compared with dual therapy and shortens the antibiotic exposure needed for cure.

Pylotrip is dispensed as a co-packaged, fixed-course regimen and is not intended for long-term or as-needed use.

Pylotrip belongs to a multi-drug therapeutic class combination:

• Lansoprazole — Proton Pump Inhibitor (PPI)
• Amoxicillin — Aminopenicillin (beta-lactam antibiotic)
• Clarithromycin — Macrolide antibiotic

Together, Pylotrip functions as an anti-H.-pylori eradication therapy.

Lansoprazole + Amoxicillin + Clarithromycin works through three complementary mechanisms:

• Lansoprazole irreversibly inhibits the H⁺/K⁺-ATPase (proton pump) in gastric parietal cells, suppressing basal and stimulated gastric acid secretion. Raising intragastric pH improves antibiotic stability and efficacy against H. pylori and promotes ulcer healing.
• Amoxicillin inhibits bacterial cell-wall synthesis by binding penicillin-binding proteins, producing bactericidal activity against H. pylori.
• Clarithromycin binds the 50S ribosomal subunit, inhibiting bacterial protein synthesis and providing bacteriostatic/bactericidal activity against H. pylori.

The three-drug combination in Lansoprazole + Amoxicillin + Clarithromycin achieves substantially higher H. pylori eradication rates than any single agent or two-drug regimen.

Pylotrip should be taken by mouth, with all three components of a dose taken together, generally before a meal, approximately 12 hours apart (e.g., morning and evening). Capsules and tablets should be swallowed whole with water and not crushed or chewed unless a physician specifically advises otherwise. Pylotrip should be taken at the same times each day to maintain consistent drug levels, and the entire prescribed course must be completed even if symptoms improve early.

Pylotrip contains clarithromycin, a strong CYP3A4 inhibitor, and lansoprazole, which raises gastric pH; both properties create clinically important interactions.

• Pimozide, ergotamine/dihydroergotamine, cisapride, astemizole, terfenadine: Co-administration with Pylotrip is contraindicated — clarithromycin raises plasma levels of these drugs via CYP3A4 inhibition, risking serious cardiac arrhythmia (including QT prolongation/torsades de pointes) or ergotism.
• Lovastatin, simvastatin: Contraindicated with Pylotrip due to markedly increased statin levels and risk of rhabdomyolysis; other statins (e.g., atorvastatin, rosuvastatin) require dose caution or temporary interruption during the course.
• Oral anticoagulants (e.g., warfarin): Clarithromycin in Pylotrip can potentiate anticoagulant effect; INR should be monitored closely during and shortly after therapy.
• Colchicine: Increased colchicine toxicity risk, especially in renal/hepatic impairment; avoid or reduce colchicine dose during Pylotrip therapy.
• Digoxin, carbamazepine, theophylline, triazolam/midazolam: Clarithromycin can raise levels of these drugs; monitoring or dose adjustment may be needed during Pylotrip therapy.
• Drugs requiring an acidic gastric pH for absorption (e.g., ketoconazole, itraconazole, atazanavir): The lansoprazole component of Pylotrip can reduce their absorption and effectiveness.
• Methotrexate (high-dose): PPIs such as the lansoprazole in Pylotrip may delay methotrexate elimination and increase toxicity risk.
• Other QT-prolonging drugs: Additive QT-prolongation risk when combined with Pylotrip; avoid concurrent use where possible.

Patients should tell their physician about all other medicines before starting Pylotrip.

Common

• Diarrhea (may be dose-limiting)
• Nausea and abdominal discomfort
• Altered or metallic taste (dysgeusia) — a well-recognized clarithromycin effect
• Headache
• Vaginal candidiasis (yeast infection) due to antibiotic use
• Skin rash

Less Common / Serious

• Clostridioides difficile-associated diarrhea/colitis, which can range from mild to life-threatening and may occur during or up to several weeks after finishing Pylotrip.
• Hepatic enzyme elevation or, rarely, hepatotoxicity.
• QT-interval prolongation and, rarely, serious ventricular arrhythmia.
• Severe hypersensitivity reactions, including anaphylaxis and severe cutaneous reactions (e.g., Stevens-Johnson syndrome) — rare but require immediate discontinuation of Pylotrip and medical attention.

Patients should seek prompt medical attention for severe or persistent diarrhea, signs of allergic reaction, jaundice, or palpitations while taking Pylotrip.

Pylotrip should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; a physician should be consulted before use. Amoxicillin is generally considered compatible with pregnancy when indicated, but data specifically on the combined use of lansoprazole and clarithromycin together in pregnancy are limited, and clarithromycin has shown adverse findings in some animal reproduction studies. Pylotrip should therefore not be used in pregnancy unless a physician determines no suitable alternative exists.

During breastfeeding, all three components of Pylotrip pass into breast milk to varying degrees. Pylotrip should be used during lactation only under medical supervision, with the infant monitored for diarrhea, thrush, or rash; a physician should weigh the benefits of treatment against potential risk to the breastfed infant.

Antibiotic Stewardship

Take Pylotrip exactly as prescribed by your physician; do not stop, extend, skip doses, or share this medicine with others without medical advice. Completing the full course is essential for successful H. pylori eradication and to reduce the risk of antibiotic resistance.

Other Precautions

• Clostridioides difficile-associated diarrhea: Can occur during or after use of Pylotrip; seek medical attention for severe, persistent, or bloody diarrhea.
• QT prolongation: Use Pylotrip with caution in patients with electrolyte disturbances (hypokalemia, hypomagnesemia), significant bradycardia, or concomitant use of other QT-prolonging drugs.
• Hepatic function: Monitor for signs of liver injury (jaundice, dark urine, unusual fatigue) during therapy with Pylotrip.
• Masking of gastric malignancy: Symptomatic response to the lansoprazole component of Pylotrip does not exclude gastric malignancy; this should be considered before starting therapy in at-risk patients.
• Superinfection: Prolonged antibiotic use in Pylotrip may result in overgrowth of non-susceptible organisms, including fungal infection.
• Clarithromycin resistance: Local H. pylori clarithromycin resistance rates should guide whether Pylotrip remains an appropriate first-line choice.

Specific data on overdose of Pylotrip as a combination are limited. Overdose could produce exaggerated effects of its components, such as severe gastrointestinal upset (nausea, vomiting, diarrhea), or effects related to excess antibiotic exposure. In case of suspected overdose of Pylotrip, seek immediate medical attention or contact a poison control center; treatment is supportive and symptomatic, as there is no specific antidote. Do not attempt home treatment for a suspected overdose.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Pediatric use: The safety and efficacy of Pylotrip as a fixed combination have not been established in pediatric patients; this regimen is generally intended for adults. See Pediatric Uses.
• Elderly: No overall differences in effectiveness have been observed, but elderly patients may have a higher prevalence of decreased hepatic, renal, or cardiac function, warranting closer monitoring during Pylotrip therapy.
• Renal impairment: Dose adjustment of the lansoprazole and amoxicillin components of Pylotrip may be required in severe renal impairment (see Dosage and Administration).
• Hepatic impairment: Clarithromycin exposure increases in hepatic impairment; use Pylotrip with caution and physician oversight, particularly if renal impairment coexists.

Pylotrip is prescribed as a fixed-course regimen, typically for 14 days (some protocols use 10 days depending on local resistance patterns and physician judgment). The full course must be completed exactly as prescribed; Pylotrip is not intended for open-ended or as-needed use, and treatment should not be shortened even if symptoms resolve early.

Proton pump inhibitor + Aminopenicillin (beta-lactam) antibiotic + Macrolide antibiotic (fixed-combination H. pylori eradication therapy)

Lansoprazole + Amoxicillin + Clarithromycin combines acid suppression with dual antibacterial action against H. pylori. Lansoprazole irreversibly blocks the gastric H⁺/K⁺-ATPase pump, reducing acid secretion and creating a gastric environment less favorable to the organism while improving antibiotic stability. Amoxicillin disrupts bacterial cell-wall synthesis, and clarithromycin inhibits bacterial protein synthesis at the ribosomal level. The combined, complementary mechanisms in Lansoprazole + Amoxicillin + Clarithromycin achieve eradication rates well above those of any single component.

The safety and efficacy of Pylotrip as a fixed triple-therapy combination have not been established in pediatric patients, and it is not approved for pediatric use. H. pylori eradication in children, when indicated, is generally managed with individually weight-based antibiotic and acid-suppression regimens selected and dosed by a pediatric specialist, not with this fixed adult-strength combination. Pylotrip should not be given to children unless specifically directed by a physician experienced in pediatric H. pylori management.